Cortigent is a subsidiary of Vivani Medical, an innovative biopharmaceutical company developing miniaturized, long-term implant technology. Cortigent develops and markets targeted neurostimulation systems based on proprietary neuroscience, microelectronics, software, and data processing capabilities. Their technology is designed to stimulate specific areas of the brain with the aim of helping patients recover critical body function.

Cortigent was formed to continue the business of Second Sight Medical Products, a pioneer in developing targeted neurostimulation systems to help patients recover critical body functions including profound blindness and the recovery of arm and hand function in patients who are partially paralyzed due to stroke. Cortigent has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its common stock. Cortigent intends to list its common stock on the Nasdaq Capital Market under the ticker symbol “CRGT.” A registration statement relating to the proposed offering has been filed with the SEC but has not yet become effective.